Keyword: Daniel O'Day
Write-offs from Gilead's Kite Pharma buyout are adding up and some analysts believe the company overpaid.
Gilead CEO Daniel O’Day’s been in his role long enough to know what investors want: more transparency and M&A clues. He gave them both Monday.
What can Gilead investors expect to see from incoming CEO Daniel O’Day? Patience, but also more deal hunting, according to the big biotech’s execs.
Call it a swap. Alexander Hardy is taking the top spot at Genentech in an executive shuffle triggered by the departure of Dan O'Day.
Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.
Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.